APUS
AMEX · Biotechnology
Apimeds Pharmaceuticals Us I
$1.91
+0.28 (+17.18%)
Financial Highlights (FY 2025)
Revenue
11.55M
Net Income
858.8K
Gross Margin
53.2%
Profit Margin
7.4%
Rev Growth
-8.4%
D/E Ratio
0.40
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 53.2% | 53.2% | 53.2% |
| Operating Margin | 7.6% | 7.0% | 7.9% |
| Profit Margin | 7.4% | 5.9% | 6.5% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 11.55M | 12.01M | 11.14M |
| Gross Profit | 6.14M | 6.39M | 5.93M |
| Operating Income | 883.0K | 834.8K | 881.1K |
| Net Income | 858.8K | 710.2K | 724.1K |
| Gross Margin | 53.2% | 53.2% | 53.2% |
| Operating Margin | 7.6% | 7.0% | 7.9% |
| Profit Margin | 7.4% | 5.9% | 6.5% |
| Rev Growth | -8.4% | +17.9% | -7.5% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 5.62M | 5.10M | 5.52M |
| Total Equity | 14.20M | 13.54M | 13.91M |
| D/E Ratio | 0.40 | 0.38 | 0.40 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 1.04M | 1.13M | 1.04M |
| Free Cash Flow | 935.0K | 714.0K | 1.10M |